Showing posts with label Medifast. Show all posts
Showing posts with label Medifast. Show all posts

Wednesday, January 11, 2012

IPG (IPGP) (RENT) (SBRA) (NAVG) (MED) (MFLX) Ratings, Price Targets

IPG Photonics (NASDAQ: IPGP), Rentrak (NASDAQ: RENT), Sabra Healthcare Reit (NASDAQ: SBRA), The Navigators Group (NASDAQ: NAVG), Medifast (NYSE: MED) and Multi-Fineline Electronix (NASDAQ: MFLX) ratings and price targets.

IPG Photonics (IPGP) had its “overweight” rating reiterated by Piper Jaffray (NYSE:PJC).

Rentrak (RENT) is now covered by Noble Financial. They placed a “buy” rating on the company.

Sabra Healthcare Reit (SBRA) had its price target raised by Morgan Keegan to $16.00.

The Navigators Group (NAVG) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.

Medifast (MED) was upgraded by Zacks Investment Research from an “underperform” rating to a “neutral” rating.

Multi-Fineline Electronix (MFLX) was upgraded by Zacks Investment Research from an “underperform” rating to a “neutral” rating.

Tuesday, May 10, 2011

NYSE's (CPE) (SPA) (MED) (DF) (TGI) Trading Over 10%

Callon Petroleum Company (NYSE:CPE), Sparton Corporation (NYSE:SPA), MEDIFAST INC (MED), Dean Foods Company (DF) and Triumph Group, Inc. (TGI) were all trading up over 10 percent on the NYSE today.

Callon Petroleum Company (CPE) was trading at $7.32, gaining $1.14, or 18.45 percent, as of 1:47 PM EDT.

Sparton Corporation (SPA) was trading at $9.20, up $1.29, or 16.31 percent.

MEDIFAST INC (MED) was trading at $23.50, rising $3.11, or 15.25 percent.

Dean Foods Company (DF) was trading at $12.30, jumping $1.32, or 12.02 percent.

Triumph Group, Inc. (TGI) was trading at $99.08, soaring $10.53, or 11.89 percent.

Wednesday, April 27, 2011

Medifast (MED) (ATHN) (GRT) LXRX) - New Ratings and Price Targets

New ratings and price targets on Medifast, Inc. (NYSE: MED), AthenaHealth (NASDAQ: ATHN), Glimcher Realty Trust (NYSE: GRT) and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).

Oppenheimer initiated coverage on AthenaHealth (ATHN). They placed an “Underperform” rating and a price target of $30.00 on the firm.

Goldman Sachs (NYSE:GS) initiated coverage on Glimcher Realty Trust (GRT). They placed a “Neutral” rating on the stock.

Wedbush initiated coverage on Lexicon Pharmaceuticals, Inc. (LXRX). They placed an “Outperform” rating and a price target of $3.00 on the company.

Capstone initiated coverage on Medifast, Inc. (MED). They placed a “Buy” rating on the shares.

Tuesday, January 4, 2011

Medifast (NYSE:MED), JAKKS Pacific (Nasdaq:JAKK), Pier 1 Imports (NYSE:PIR), Dollar Tree (Nasdaq:DLTR), Sotheby's (NYSE:BID) Among Top Picks of Wedbus

In the Consumer/Retail space, Wedbush released its top picks and those that may be a disaster in 2011. Among the top picks are Medifast (NYSE:MED), JAKKS Pacific (Nasdaq:JAKK), Pier 1 Imports (NYSE:PIR), Dollar Tree (Nasdaq:DLTR) and Sotheby's (NYSE:BID)

Particularly noted in the luxury space was Sotheby's, which, along with other luxury retailers, is being watched closely to see if the more affluent are starting to spend again.

Also listed among their favorites were Children's Place (Nasdaq:PLCE), Talbots (NYSE:TLB) and Foot Locker (NYSE:FL).

Those with a good chance of underperforming in 2011 include American Eagle (NYSE:AEO), Family Dollar (NYSE:FDO) and Helen of Troy (Nasdaq:HELE).

Monday, December 6, 2010

Medifast (NYSE:MED) Acceleration to Pick Up

Medifast (NYSE:MED) seems to have only just begun a multi-channel expansion which should propel them strongly into the future, according to Canaccord Genuity.

"We reiterate our thesis that Medifast is in the early stages of a multi-channel expansion phase with an attractive business model that should generate strong earnings and cash flow growth on top of well above average returns on equity and capital...Raising F2011E revenue to $332M from $328M to reflect clinic growth, offset by higher initial costs to keep EPS unchanged," said Canaccord.

They maintain a "Buy" rating on Medifast, which closed Friday at $27.45, surging $1.10, or 4.17 percent. Canaccord has a price target on them of $40.